https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]>